Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Person › Details

Pilar de la Huerta Martinez (Sygnis Pharma AG)

de la Huerta Martinez, Pilar (Sygnis Pharma 201303– CEO + CFO before Genetrix CEO before Zeltia)


Organisations Organisation Sygnis Pharma AG
  Today Sygnis AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard)
  Group Expedeon (Group)
  Former/major organisation Genetrix S.L.
  Today Expedeon Biotech S.L.U.
  Group Expedeon (Group)
Products Product BIOTECH
  Product 2 Qualiphi® DNA polymerase

Sygnis Pharma AG. (3/4/13). "Press Release: Sygnis Pharma AG Secures Further Financial Resources with Shareholder Loan". Heidelberg.

SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03, Prime Standard) today reports on the granting of a shareholder loan for a total amount of up to EUR 0.7 million by its main shareholders Genetrix Life Sciences, A.B., Uppsala (Sweden) and dievini Hopp BioTech holding GmbH & Co. KG, Walldorf (Germany) with an interestrate at customary market conditions. As a result this loan, which is payable on demand and subject to a condition precedent, secures the financing of SYGNIS' existing operations, according to the present plans, until mid 2013. The loan is unsecured and is due for repayment not before the end of 2015.

**** end of ad hoc ****

For further information please contact:

Peter Willinger
Tel: +49 6221 454 836

### Disclaimer

This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.

SYGNIS Pharma AG, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany,, Tel: +49-6221-454-6, Fax: +49-6221-454-700

Record changed: 2020-06-26


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Pilar de la Huerta Martinez

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

» top